National Coverage Determination Will Make TAVR Available to More Patients at More Centers

Aug 12, 2019 | DAIC Articles

As we usher in a new era for treating patients with aortic stenosis, we have been reflecting on the evolution of the technology used for transcatheter aortic valve replacement (TAVR) and the evolution of our collaborative process as a team over years as a center in the PARTNER 3 clinical trial. PARTNER 3, which this year showed low-risk patients fared as well or better with TAVR as they did with surgery.